Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

1.

Dissecting the Immune-Response to MF59®-Adjuvanted and Non-Adjuvanted Seasonal Influenza Vaccines in Children Less Than Three Years of Age.

Zedda L, Forleo-Neto E, Vertruyen A, Raes M, Marchant A, Jansen W, Clouting H, Arora A, Beatty ME, Galli G, Del Giudice G, Castellino F.

Pediatr Infect Dis J. 2014 Jul 16. [Epub ahead of print]

PMID:
25037034
[PubMed - as supplied by publisher]
2.

Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59®-adjuvanted influenza vaccine in infants and young children.

Nolan T, Bravo L, Ceballos A, Mitha E, Gray G, Quiambao B, Patel SS, Bizjajeva S, Bock H, Nazaire-Bermal N, Forleo-Neto E, Cioppa GD, Narasimhan V.

Vaccine. 2014 Sep 12. pii: S0264-410X(14)01226-2. doi: 10.1016/j.vaccine.2014.08.068. [Epub ahead of print]

PMID:
25223266
[PubMed - as supplied by publisher]
3.

Comparison of the safety and immunogenicity of an MF59(®)-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects.

Frey SE, Reyes MR, Reynales H, Bermal NN, Nicolay U, Narasimhan V, Forleo-Neto E, Arora AK.

Vaccine. 2014 Sep 3;32(39):5027-34. doi: 10.1016/j.vaccine.2014.07.013. Epub 2014 Jul 18.

PMID:
25045825
[PubMed - in process]
4.

Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children.

Solares AR, Aragon CG, Pivaral RU, Prado-Cohrs D, Sales-Carmona V, Pellegrini M, Groth N.

J Infect Dev Ctries. 2014 Sep 12;8(9):1160-8. doi: 10.3855/jidc.4594.

PMID:
25212080
[PubMed - in process]
Free Article
5.

Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.

Vesikari T, Forstén A, Herbinger KH, Cioppa GD, Beygo J, Borkowski A, Groth N, Bennati M, von Sonnenburg F.

Vaccine. 2012 Feb 8;30(7):1388-96. doi: 10.1016/j.vaccine.2011.12.009. Epub 2011 Dec 20.

PMID:
22192847
[PubMed - indexed for MEDLINE]
6.

Oil-in-water emulsion adjuvant with influenza vaccine in young children.

Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, Schmitt HJ, Baehner F, Borkowski A, Tsai TF, Clemens R.

N Engl J Med. 2011 Oct 13;365(15):1406-16. doi: 10.1056/NEJMoa1010331.

PMID:
21995388
[PubMed - indexed for MEDLINE]
Free Article
7.
8.

MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis.

Banzhoff A, Pellegrini M, Del Giudice G, Fragapane E, Groth N, Podda A.

Influenza Other Respir Viruses. 2008 Nov;2(6):243-9. doi: 10.1111/j.1750-2659.2008.00059.x. Review.

PMID:
19453401
[PubMed - indexed for MEDLINE]
9.

Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.

Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, Podda A.

Pediatr Infect Dis J. 2009 Jul;28(7):563-71. doi: 10.1097/INF.0b013e31819d6394.

PMID:
19561422
[PubMed - indexed for MEDLINE]
10.

Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study.

Della Cioppa G, Vesikari T, Sokal E, Lindert K, Nicolay U.

Vaccine. 2011 Nov 3;29(47):8696-704. doi: 10.1016/j.vaccine.2011.08.111. Epub 2011 Sep 9.

PMID:
21906647
[PubMed - indexed for MEDLINE]
11.

A dose-range study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration.

Della Cioppa G, Nicolay U, Lindert K, Leroux-Roels G, Clement F, Castellino F, Galli G, Groth N, Levin Y, Del Giudice G.

Hum Vaccin Immunother. 2014 Apr 14;10(6). [Epub ahead of print]

PMID:
24732325
[PubMed - as supplied by publisher]
12.

MF59 adjuvanted seasonal and pandemic influenza vaccines.

Tsai TF.

Yakugaku Zasshi. 2011;131(12):1733-41. Review.

PMID:
22129867
[PubMed - indexed for MEDLINE]
Free Article
13.

Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults.

Della Cioppa G, Nicolay U, Lindert K, Leroux-Roels G, Clement F, Castellino F, Galli G, Groth N, Del Giudice G.

Hum Vaccin Immunother. 2012 Feb;8(2):216-27. doi: 10.4161/hv.18445. Epub 2012 Feb 1.

PMID:
22426371
[PubMed - indexed for MEDLINE]
14.

Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine.

Song JY, Cheong HJ, Noh JY, Seo YB, Choi WS, Cho GJ, Hwang TG, Kim WJ.

J Med Virol. 2013 Sep;85(9):1591-7. doi: 10.1002/jmv.23630.

PMID:
23852684
[PubMed - indexed for MEDLINE]
15.

Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine.

Cheong HJ, Song JY, Heo JY, Noh JY, Choi WS, Park DW, Wie SH, Kim WJ.

Clin Vaccine Immunol. 2011 Aug;18(8):1358-64. doi: 10.1128/CVI.05111-11. Epub 2011 Jun 29.

PMID:
21715575
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Immunogenicity and Tolerability of an MF59®-Adjuvanted, Egg-Derived, A/H1N1 Pandemic Influenza Vaccine in Children 6-35 Months of Age.

Knuf M, Leroux-Roels G, Rümke HC, Abarca K, Rivera L, Lattanzi M, Pedotti P, Arora A, Kieninger-Baum D, Cioppa GD.

Pediatr Infect Dis J. 2014 Jun 20. [Epub ahead of print]

PMID:
24978857
[PubMed - as supplied by publisher]
17.

Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination.

Soonawala D, Rimmelzwaan GF, Gelinck LB, Visser LG, Kroon FP.

PLoS One. 2011 Jan 31;6(1):e16496. doi: 10.1371/journal.pone.0016496.

PMID:
21304982
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.

Hatz C, von Sonnenburg F, Casula D, Lattanzi M, Leroux-Roels G.

Vaccine. 2012 May 14;30(23):3470-7. doi: 10.1016/j.vaccine.2012.03.017. Epub 2012 Mar 22.

PMID:
22446638
[PubMed - indexed for MEDLINE]
19.

A 1-year follow-on study from a randomised, head-to-head, multicentre, open-label study of two pandemic influenza vaccines in children.

de Whalley P, Walker W, Snape MD, Oeser C, Casey M, Moulsdale P, Harrill C, Andrews N, Hoschler K, Thompson B, Jones C, Chalk J, Kerridge S, Tomlinson R, Heath PT, Finn A, Faust S, Miller E, Pollard AJ.

Health Technol Assess. 2011 Dec;15(45):v-vi, xi-xiii, 1-128. doi: 10.3310/hta15450.

PMID:
22257497
[PubMed - indexed for MEDLINE]
Free Article
20.

Is the adjuvanted influenza vaccine more effective than the trivalent inactivated vaccine in the elderly population? Results of a case-control study.

Spadea A, Unim B, Colamesta V, Meneghini A, D'Amici AM, Giudiceandrea B, La Torre G.

Vaccine. 2014 Sep 15;32(41):5290-4. doi: 10.1016/j.vaccine.2014.07.077. Epub 2014 Aug 1.

PMID:
25087677
[PubMed - in process]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk